This news release constitutes a “designated news release” for the purposes of the Company’s amended and restated prospectus supplement dated November 18, 2025, to its short form base shelf prospectus dated May 15, 2025MIAMI, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company, is pleased to announce the release of the following letter to its shareholders by Michel Amar, Chairman and Chief Executive Offi ...

SECAUCUS, N.J., Dec. 19, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading national provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a presentation and Q&A session at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, ...

Quest Diagnostics Incorporated (DGX), headquartered in Secaucus, New Jersey, is a leader in diagnostic information services. The company operates numerous patient service centers and laboratories worldwide, providing routine, esoteric, and advanced testing for conditions including cancer, infectious diseases, and cardiovascular diseases. It supports physicians, hospitals, and employers through molecular diagnostics, anatomic pathology, and health IT solutions. With operations in diagnostic information se ...

PresentationOperator Hello, and thank you for joining us for the IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025. IAccess Alpha host virtual investor conferences featuring company source from investors with a track record of generating alpha. Today, you will hear presentations from 15 selected companies. IAccess Alpha holds 4 virtual investor conferences annually, 1 per quarter. The next event will be the IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 scheduled for Mar ...

Core Insights - Digi Power X Inc. has appointed Jagan Jeyapaul as Chief Technology Officer to lead its technology roadmap and AI infrastructure initiatives [1][3] Company Overview - Digi Power X is an innovative energy infrastructure company focused on developing Tier III-certified modular AI data centers and expanding sustainable energy assets [4] Leadership Appointment - Jagan Jeyapaul brings extensive experience from Silicon Valley, having worked at Oracle, Equinix, and VeriSign, where he modernized cloud and data-center platforms and automated over 200 data centers [2] - As CTO, he will oversee the ARMS 200 Tier-3 modular data-center platform and manage the NeoCloudz GPU-as-a-Service platform, preparing for AI data processing in 2026 [3] Strategic Goals - The company aims to strengthen its position in AI infrastructure and accelerate Tier-3 deployments under Jeyapaul's leadership [4]

Core Insights - Digi Power X Inc. is advancing its AI infrastructure roadmap, focusing on the deployment of its ARMS 200 Tier III modular data center platform and launching its GPU-as-a-Service platform NeoCloudz in Q1 2026 [2][3][11] Deployment and Infrastructure - The deployment of the ARMS 200 platform will commence in Q1 2026 across U.S. Tier III facilities, marking a shift from cryptocurrency mining to AI-optimized infrastructure [3] - The first NVIDIA B200 GPU cluster has been completed at the Alabama campus, optimized for high-density integration, liquid cooling, low-latency networking, and multi-megawatt scalability [7][8] Patent and Collaboration - The company has filed a patent application for the ARMS 200 platform with the USPTO, covering key components of the architecture [4] - Digi Power X is collaborating with Supermicro to integrate the ARMS 200 modular cluster line, enabling global distribution through Supermicro's enterprise channel [5][6] AI Transition and Capacity - The company is converting its existing power capacity into Tier III AI infrastructure, targeting 195 MW operational by 2027, including 140 MW of critical Tier III AI capacity [12] - A phased deployment plan is in place for 2026, with specific targets for each quarter [16] Financial Position - As of November 30, 2025, the company reported total liquidity of approximately $97 million, up from $85 million on October 31, 2025, positioning it to accelerate its AI infrastructure development [14][16] - The company holds approximately 123 BTC and 1,000 ETH, with a fair market value of around $3 million for ETH, and has generated significant revenue from its mining activities [20] Market Strategy - The company is utilizing its at-the-market equity offering to raise capital for its AI infrastructure strategy, enhancing its ability to scale operations and pursue growth initiatives [17]

Core Insights - The discussion focuses on the elevated utilization levels in the industry, which were initially thought to be a temporary effect of the COVID-19 pandemic but have persisted over time [2]. Group 1: Utilization Trends - Utilization levels have remained quite elevated, contrary to expectations that they would decline post-COVID [2]. - There is a growing interest and inquiry regarding the reasons behind the sustained high utilization levels [2]. - Expectations are set for utilization to remain elevated relative to historical levels, indicating a potential shift in industry dynamics [2].

Financial Data and Key Metrics Changes - The company expects organic revenue growth to be in the range of 4.5%-5% for the full year, with year-to-date organic revenue growth at 4.8% [27] - Operating margin rates are growing from last year, with an expectation of expansion between 75 and 150 basis points over the next three years [31][32] Business Line Data and Key Metrics Changes - The consumer channel is growing at approximately 35% year-over-year, approaching $100 million in revenue [8] - Advanced diagnostics testing areas are growing in the low double digits, contributing close to $1 billion [12] Market Data and Key Metrics Changes - The company has gained access to new markets, including four states with a new payer, which is driving higher utilization [3] - The consumer segment is expanding as patients take more ownership of their health, contributing to increased testing [4] Company Strategy and Development Direction - The company is focusing on partnerships and collaborations to enhance its consumer testing offerings, such as with WHOOP and Oura [10] - Project Nova is expected to incur one-time costs between $250-$310 million over the next six to seven years, with anticipated benefits starting in 2027 [42][50] Management's Comments on Operating Environment and Future Outlook - Management is optimistic about the potential delay of PAMA, which could positively impact revenue [53] - The company is confident in its growth momentum, driven by utilization, consumer engagement, and advanced diagnostics [137] Other Important Information - The company is preparing for potential impacts from the expiration of ACA subsidies, estimating a 30 basis point impact on volumes and revenue next year [70] - The company is also focused on evidence generation and operational rigor to drive adoption of new tests like Haystack [91] Q&A Session Summary Question: Can you discuss the consumer channel and its growth? - The consumer channel is growing nicely, with expectations of reaching $250 million in revenue in the future, currently growing at 35% year-over-year [8] Question: How is the advanced diagnostics segment performing? - Advanced diagnostics testing areas are growing in the low double digits, contributing significantly to overall revenue [12] Question: What are the expectations for Project Nova? - Project Nova is expected to incur costs of $250-$310 million, with benefits anticipated starting in 2027 [42][50] Question: How does management view the potential impact of PAMA? - Management is optimistic about a potential delay in PAMA, which could help avoid a $100 million impact [53][60] Question: What are the key growth drivers for the company? - Key growth drivers include strong utilization, consumer momentum, and advanced diagnostics offerings [137]

Financial Data and Key Metrics Changes - The company expects organic revenue growth to be in the range of 4.5%-5% for the full year, with year-to-date organic revenue growth at 4.8% [27] - Operating margin rates are growing from last year, with an expectation of expansion between 75 and 150 basis points over the next three years [31][32] Business Line Data and Key Metrics Changes - The consumer channel is growing at approximately 35% year-over-year, approaching $100 million in revenue [8] - Advanced diagnostics testing areas are growing in the low double digits, contributing close to $1 billion [12] Market Data and Key Metrics Changes - The company has gained access to new markets, including four states with a new payer, which is driving higher utilization [3] - The consumer segment is expanding as patients take more ownership of their health, contributing to increased testing [4] Company Strategy and Development Direction - The company is focusing on partnerships and collaborations to enhance its consumer testing offerings, such as with WHOOP and Oura [10] - Project Nova is expected to incur one-time costs between $250-$310 million over the next six to seven years, with anticipated benefits starting in 2027 [42][50] Management's Comments on Operating Environment and Future Outlook - Management is optimistic about the potential delay of PAMA, which could positively impact revenue [53] - The company is confident in its growth momentum, driven by utilization, consumer engagement, and advanced diagnostics [137] Other Important Information - The company is preparing for potential impacts from the expiration of ACA subsidies, estimating a 30 basis point impact on volumes and revenue next year [70] - The company is also focused on evidence generation and operational rigor to drive adoption of new tests like Haystack [91] Q&A Session Summary Question: Can you discuss the consumer channel and its growth? - The consumer channel is growing nicely, with expectations of reaching $250 million in revenue in the future, currently growing at 35% year-over-year [8] Question: How is the advanced diagnostics segment performing? - Advanced diagnostics testing areas are growing in the low double digits, contributing significantly to overall revenue [12] Question: What are the expectations for Project Nova? - Project Nova is expected to incur costs of $250-$310 million, with benefits anticipated starting in 2027 [42][50] Question: How does management view the potential impact of PAMA? - Management is cautiously optimistic about a potential delay in PAMA, which could mitigate revenue impacts [53] Question: What are the key growth drivers for the company? - Key growth drivers include strong utilization, consumer engagement, and advanced diagnostics [137]

Financial Data and Key Metrics Changes - The company expects organic revenue growth for the full year to be in the range of 4.5%-5%, with year-to-date organic revenue growth at 4.8% [28] - Operating margin rate is growing from last year, with an expectation of expansion between 75 and 150 basis points over the next three years [32][34] Business Line Data and Key Metrics Changes - The consumer channel is growing at approximately 35% year-over-year, approaching $100 million in revenue [7] - Advanced diagnostics testing areas are growing in double digits, contributing close to $1 billion [10] Market Data and Key Metrics Changes - Utilization rates remain elevated, driven by factors such as increased access and chronic illness screening [2][5] - The company has gained access with new payers, expanding its reach in multiple states [3] Company Strategy and Development Direction - The company is focusing on consumer health and wellness, leveraging partnerships with companies like WHOOP and Oura to drive growth [8][9] - Project Nova is expected to incur one-time costs between $250-$310 million over the next six to seven years, aimed at transforming lab operations and improving productivity [42][50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential delay of PAMA, which could positively impact revenue [52][56] - The company is confident in its growth momentum, citing strong utilization and advanced diagnostics as key drivers [139] Other Important Information - The company is preparing for potential impacts from the expiration of ACA subsidies, estimating a 30 basis point impact on volumes and revenue next year [67] - The company is also focused on evidence generation and operational rigor to drive adoption of new tests like Haystack [90][92] Q&A Session Summary Question: Can you discuss the consumer channel's growth? - The consumer channel is growing at about 35% year-over-year, nearing $100 million in revenue [7] Question: What are the expectations for Project Nova? - Project Nova is expected to incur costs of $250-$310 million over the next six to seven years, with benefits anticipated starting in 2027 [42][50] Question: How does the company view the potential impact of PAMA? - Management is optimistic about a potential delay in PAMA, which could positively affect revenue [52][56] Question: What is the company's strategy regarding partnerships and internal test development? - The company balances organic development, in-licensing, and partnerships to expand its test offerings [116] Question: How is the pipeline for acquisitions looking? - The acquisition pipeline is healthy, with a focus on physician outreach books of business [135]